CD226

Across TCGA pan-cancer cohorts, CD226 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD226 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD226 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CD226 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, ESCA, and STAD are the cancer types where CD226 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.435	.011	24	view →
ESCA	OS	Median	III,IV	0.117	0.574	.001	21	view →
STAD	OS	Median	II,III,IV	0.250	0.678	.005	12	view →
KIRP	DFS	Median	All	0.589	0.857	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	All	0.249	0.619	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD226–UCEC (DFS)

Open the UCEC breakdown →